Welcome to our dedicated page for Relay Therapeutics news (Ticker: RLAY), a resource for investors and traders seeking the latest updates and insights on Relay Therapeutics stock.
Relay Therapeutics, Inc. (NASDAQ: RLAY) is a clinical-stage precision medicine company dedicated to transforming the drug discovery process. Headquartered in Cambridge, Massachusetts, the company focuses on combining advanced computational and experimental technologies to develop life-changing therapies. Since its inception in 2016, Relay Therapeutics has been pioneering a new paradigm in the pharmaceutical industry by placing protein motion at the core of drug discovery.
The company's flagship platform, Dynamo™, integrates cutting-edge computational and experimental approaches to target protein structures that are either intractable or inadequately addressed by current therapies. This platform has enabled the development of multiple promising drug candidates, particularly in the fields of precision oncology and genetic diseases. Key product candidates include RLY-4008, RLY-2608, and GDC-1971 (formerly RLY-1971).
Relay Therapeutics' recent corporate highlights include significant advancements in its RLY-2608 program, aimed at treating patients with PI3Kα-mutated HR+/HER2- breast cancer. The company's development pipeline has been robust, with expectations to disclose innovative programs later this year.
Financially, as of March 31, 2024, Relay Therapeutics reported cash, cash equivalents, and investments totaling approximately $749.6 million. This financial stability is projected to fund the company's operations into the second half of 2026. The company’s revenue for Q1 2024 was $10 million, primarily derived from milestone payments under a collaboration agreement with Genentech, Inc.
Relay Therapeutics has also established strategic partnerships with notable entities such as Pfizer, Nextech, and Genentech, enhancing its capability to advance its clinical and preclinical programs. The company’s innovative approach has attracted significant investment from third-party ventures, including GV (formerly Google Ventures) and Alexandria Venture Investments.
Relay Therapeutics continues to push the boundaries of what’s possible in drug discovery, aiming to improve the lives of millions of patients through precision medicine.
Relay Therapeutics presented new preclinical data for RLY-2608, a targeted PI3Kα inhibitor, at the virtual AACR-NCI-EORTC conference. This novel allosteric inhibitor demonstrated preferential binding to mutant PI3Kα without affecting wild-type forms, achieving significant tumor regression in animal models. RLY-2608 could potentially address over 100,000 patients annually in the U.S. Its targeted approach may double the patient population compared to existing therapies. The first-in-human trial is expected in H1 2022, indicating a promising development in precision oncology.
Relay Therapeutics (Nasdaq: RLAY) announced the presentation of initial clinical data for RLY-4008 and preclinical data for RLY-2608 at the AACR-NCI-EORTC Molecular Targets Conference from October 7-10, 2021. RLY-4008 is a selective FGFR2 inhibitor currently in a first-in-human trial, while RLY-2608, a pan-mutant PI3Kα inhibitor, is set to start its first trial in early 2022. A conference call will occur on October 8 to discuss the results.
Relay Therapeutics (Nasdaq: RLAY) has selected RLY-2608 as a development candidate for PI3Kα mutant inhibitors and plans to initiate a first-in-human study in H1 2022. RLY-2608 effectively inhibits mutants H1047X, E542X, and E545X, impacting over 100,000 patients annually in the U.S. The company reported Q2 2021 financial results, revealing a net loss of $193.4 million. Additionally, Relay has partnered with EQRx to develop oncology medicines, sharing development costs and profits equally. The company expects sufficient cash to fund operations into 2024.
Relay Therapeutics (Nasdaq: RLAY) announced plans to report its second quarter 2021 financial results on August 12, 2021, after market closure. The company will not hold a teleconference to discuss these results. Relay Therapeutics is a clinical-stage precision medicine firm focused on transforming drug discovery using its innovative Dynamo™ platform, targeting oncology and genetic diseases. The company aims to tackle challenging protein targets through an integration of computational and experimental technologies.
Relay Therapeutics (Nasdaq: RLAY) will participate in two upcoming fireside chats: at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 3:50 pm ET, and at the JMP Securities Life Science Conference on June 17, 2021, at 10:30 am ET. These discussions will be webcast live and accessible via the Investor page of Relay's website. Archived replays will be available for 90 days post-event. Relay Therapeutics, a clinical-stage precision medicine company, aims to enhance drug discovery using its Dynamo™ platform focused on oncology and genetic diseases.
Relay Therapeutics (Nasdaq: RLAY) will participate in a fireside chat at the Cowen 2nd Annual Virtual Oncology Innovation Summit on May 20, 2021, at 11:20 AM ET. The event will be webcast live and accessible via the Investor page of Relay's website. A replay of the chat will be available for 90 days post-event, until August 18, 2021. Relay Therapeutics focuses on precision medicine, using its Dynamo™ platform to enhance drug discovery for challenging protein targets, particularly in oncology and genetic diseases.
Relay Therapeutics reported its first quarter 2021 financial results, highlighting a cash reserve of approximately $726.1 million, up from $678.1 million at the end of 2020, ensuring funding into 2024. The company focuses on advancing its clinical programs, including RLY-1971 and RLY-4008, and has made its first acquisition of ZebiAI to enhance its Dynamo™ platform. However, the net loss widened to $42.2 million, compared to $24.9 million in Q1 2020, with increased R&D and G&A expenses.
Relay Therapeutics (Nasdaq: RLAY) has appointed Dr. Patrick Riley as the senior vice president of artificial intelligence, enhancing its computational strength in drug discovery. With 15 years of experience from Google, Dr. Riley will spearhead a computational team focused on applying AI to drug development. His expertise in machine learning and data science is expected to strengthen Relay's innovative approach, particularly following its recent acquisition of ZebiAI. The company aims to tackle challenging protein targets to deliver transformative therapies.
Relay Therapeutics (Nasdaq: RLAY) will participate in a fireside chat at the Bank of America 2021 Health Care Conference on May 11, 2021, at 8:45 a.m. ET. This event can be accessed live via Relay’s Investor page, with an archived replay available for 24 hours post-event, until August 13, 2021. Relay Therapeutics is a clinical-stage precision medicines company utilizing its innovative Dynamo™ platform to advance small molecule discoveries for targeted oncology and genetic diseases.
Relay Therapeutics announced the appointments of Tara O'Meara as Senior VP of Clinical Development Operations and Dr. Charles Ferté as VP, Global Medical Lead for RLY-4008. Both bring extensive experience in drug development, aimed at enhancing Relay's clinical capabilities. O'Meara has over a decade of experience in rare genetic diseases and oncology, while Dr. Ferté has 15 years in oncology R&D, including roles at AstraZeneca. This leadership expansion is expected to strengthen Relay's drug pipeline as they continue developing therapies for critical conditions.
FAQ
What is the current stock price of Relay Therapeutics (RLAY)?
What is the market cap of Relay Therapeutics (RLAY)?
What is Relay Therapeutics' primary focus?
Where is Relay Therapeutics headquartered?
What is the Dynamo™ platform?
What are some of Relay Therapeutics' key product candidates?
How financially stable is Relay Therapeutics?
Which significant partnerships has Relay Therapeutics established?
What recent progress has Relay Therapeutics made?
How does Relay Therapeutics plan to use its financial resources?
When was Relay Therapeutics founded?
What makes Relay Therapeutics' approach unique?
